Vimta Labs Limited · NSE:VIMTALABS
Vimta Labs — Q3 FY2024 Earnings Presentation
28 slides from Vimta Labs's earnings presentation, Jan 31, 2024
Slide 1: Regulation 30 filing cover letter to stock exchanges
Vimta Labs Limited Registered Office 142, IDA Phase II, Cherlapally Hyderabad-500 051 ,Telangana, India T:+91 4027264141 F : +91 40 2726 3657 Driven by Quality. Inspired by Science. VLL SE 083\2023 24 Date: 31.01.2024 Listing Centre Asst Vice President B S F Limited National Stock Exchange of India
Slide 2: Vimta Labs Limited Investor Presentation Q3 & 9M FY24
Vimta Labs Limited Investor Presentation Q3 & 9M FY24 1
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Contents
Contents Q3 & 9M FY24 Earnings 1 Company Overview 2 Industry Landscape 3 Our Competitive Advantage 4 Way Forward 5 3
Slide 5: Q3 & 9M FY24 Earnings
Q3 & 9M FY24 Earnings ▪ Q3 & 9M FY24 Highlights ▪ Key Metrics: Q3 & 9M FY24 ▪ Profit & Loss Statement ▪ Balance Sheet ▪ Financial Track Record ▪ Shareholding Pattern 01 4
Slide 6: Q3 & 9M FY24 Highlights
Q3 & 9M FY24 Highlights Q3FY24 Earnings Highlights ➢ Total Income for Q3FY24 was at Rs. 826 Mn a growth of 5.2% YoY ➢ EBITDA for Q3FY24 was Rs. 227 Mn; EBITDA margin was at 27.5% ➢ Q3FY24 PAT was at Rs. 101 Mn ➢ Basic EPS in Q3FY24 was Rs. 4.6 9MFY24 Earnings Highlights ➢ Total Income for 9MFY24 was
Slide 7: Key Metrics: Q3 & 9MFY24
Key Metrics: Q3 & 9MFY24 Q3FY24 SNAPSHOT Total Income1 (In ₹ Mn) EBIDTA & EBIDTA Margin1 (In ₹ Mn, %) PAT & PAT Margin1 (In ₹ Mn, %) Basic EPS (In ₹) 13% 12% 29% 28% 125 14% 24% 8% 250 12% 225 5 100 200 10% 175 75 150 8% 125 6% 5.2% 0.7% 1.1% 50 100 785 754 826 75 4% 50 226 179 227 25 102 63 101 2%
Slide 8: Profit & Loss Statement
Profit & Loss Statement Particulars (₹ Mn) Q3 FY24 Q3 FY23 YoY (%) Q2 FY24 QoQ(%) 9M FY24 9M FY23 YoY (%) Revenue from Operations 817 774 5.6% 734 11.3% 2,386 2,364 0.9% Other Income 9 11 20 35 28 Total Income 826 785 5.2% 754 9.4% 2,421 2,391 1.2% Material and Testing Costs 197 173 182 583 529 Cost
Slide 9: Financial Track Record
Financial Track Record TOTAL INCOME (₹ Mn) PROFITABILITY (₹ Mn) EBITDA & EBITDA Margin PAT & PAT Margin 31% 15% 18% 25% 29% 15% 10% 20.5% 44.0% 4% 91.6% 1,837 2,115 2,797 3,216 CAGR 330 538 817 984 CAGR 68 214 413 482 CAGR FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 Total Revenue EBI
Slide 10: Shareholding Pattern
Shareholding Pattern Shareholding as on 31st December 2023 Share Information as on 31st December 2023 NSE Ticker VIMTALABS BSE Ticker 524394 Market Cap (INR Cr) 895 % free-float 63.02% Others Promoters Free-float market cap (INR Cr) 564 58.7% 37.0% Total Debt (INR Mn) 157 Cash & Cash Equivalents (IN
Slide 11: Company Overview
Company Overview ▪ Vimta Labs at a Glance ▪ Our Journey ▪ Services ▪ Geographical Presence ▪ Management ▪ Accreditation 02 10
Slide 12: Vimta Labs at a Glance
Vimta Labs at a Glance Established in 1984, VIMTA is one of India’s most renowned companies for contract research and testing, recognized for its high quality, cutting edge technology enabled wide spectrum, reliable services and vast experience. The company’s broad capabilities span across biologics
Slide 13: Our Journey
Our Journey ` ` Infrastructure People Investment Capabilities Revenues Pharma & Biopharma: Discovery & 2023 400,000+ ft2 1400+ 492 M development services; Food; 3,216 M Environment; Clinical Diagnostics; Electronics 2015 Analytical – Pharma, Biopharma & 400,000+ ft2 1000+ 580 M Food; Clinical Resear
Slide 14: Our Offerings (1/3)
Our Offerings (1/3) Drug discovery and development support Food & Agriculture Electronics & Environment Testing Services Clinical Diagnostics & Consultancy to Lifesciences Electricals Testing Industry Offerings Pharma Analytical Clinical Research Preclinical Support Industry Pharmaceuticals Pharmace
Slide 15: Our Offerings (2/3)
Our Offerings (2/3) Drug discovery and development support Food & Agriculture Electronics & Environment Testing Electricals Testing Clinical Diagnostics to Lifesciences Services & Consultancy Industry Offerings Food Testing Electronics & Electricals Testing No. of Laboratories 8 1 Accreditations & F
Slide 16: Our Offerings (3/3)
Our Offerings (3/3) Drug discovery and development support Food & Agriculture Electronics & Environment Testing Clinical Diagnostics to Lifesciences Services Electricals Testing & Consultancy Industry Offerings Clinical Diagnostics Environment Testing & Consultancy No. of Laboratories 2 (regional re
Slide 17: Geographical Presence
Geographical Presence Headquartered in Hyderabad, VIMTA has 19 laboratories across India, with a total laboratory space of over 400,000 sq. ft. Hyderabad (Headquarters) Food Clinical Diagnostics Pharma Electronics & Electrical Environment Food Environment Clinical Diagnostics Ahmedabad Chennai Noida
Slide 18: Key Management Team
Key Management Team S P Vasireddi Harita Vasireddi Sreenivas Neerukonda Executive Chairman Managing Director Executive Director Dr. S P Vasireddi is a Scientist – Technocrat – Harita has close to 25 years of Sreenivas’s core competencies include Entrepreneur having more than 45 years of experience i
Slide 19: Key Management Team (Cont'd)
Key Management Team (Cont’d) Harriman Vungal Suresh Kumar Narahari Naidu D.R. Executive Director - Operations President Chief Financial Officer Harriman was inducted to the Board as Suresh have more than two decades Narahari has close to 15 years of one of the Promoter Directors in 1990 of experienc
Slide 20: Industry Landscape
Industry Landscape ▪ Market Opportunity ▪ Factors Driving Industry Growth 03 19
Slide 21: Markets Opportunity
Markets Opportunity Pharmaceutical & Preclinical Food Testing Clinical Testing Environment Electronics Biopharmaceuticals Testing Testing 957.6 Global 405.5 127.3 124.7 76.6 40.5 76.2 19.5 11.1 20.2 6.8 13.4 2020 | 2028 2023 | 2028 2022 | 2032 2022 | 2028 2022 | 2030 2021 | 2031 (USD bn) CAGR: 11.3%
Slide 22: Factors Driving Industry Growth
Factors Driving Industry Growth Drug Electrical & Food Environment Discovery & Electronics Diagnostics Testing Testing Development Testing Increasing demand Growing international Surge in demand for Increase in Health risks from for new drug food regulations, certification services regulations to co
Slide 23: Our Competitive Advantage
Our Competitive Advantage ▪ Our Position in the CRTO Landscape ▪ Our Strength 04 22
Slide 24: Our Position in the CRTO Landscape
Our Position in the CRTO Landscape 1 Pharma Analytical & Preclinical 4 Food Testing #1 in India #1 in India Customers – 90% of India top 20 Customers – 70% of India top 10 30% revenues from overseas 2 Clinical Research 5 Environment Among the most reputed CROs in India Among top 5 in India 80% of re
Slide 25: Our Strengths
Our Strengths QUALITY CUSTOMER Long & successful CENTRICITY regulatory track Long term record – cGMP, GLP, partnerships with GCP customers INFRASTRUCTURE KNOWLEDGE Unparalleled lab Multi-disciplinary, infrastructure in the knowledgeable, skilled country. Gold LEED and trained manpower certified Viva
Slide 26: Way Forward
Way Forward ▪ Our Key Growth Drivers & Strategies 05 25
Slide 27: Our Key Growth Drivers & Strategies
Our Key Growth Drivers & Strategies Favourable markets Core business strategies Core operational strategies Best practices ✓ Growth momentum ✓ Capacity expansions ✓ Operational excellence ✓ Good corporate in markets ✓ Service innovations ✓ Hiring right talent governance ✓ Growing demand ✓ Penetratio
Slide 28: Thank You
Thank You January 2024 VIMTA LABS LIMITED INVESTOR RELATIONS AT Registered Office Vimta Labs Ltd. Plot Number 142, IDA Phase 2 Narahai Naidu Dodda, CFO Cherlapally, Hyderabad Narahai.Dodda@vimta.com Telangana, India. 500051 NSE: VIMTALABS, BSE: 524394 ISIN: INE579C01029 Rahul Thakur Advait Bhadekar